Botox, Dysport, and Daxxify are all injectable wrinkle relaxers used to soften expression lines on the face. If you have been researching any of these treatments, you may have noticed that they are often described in similar ways. All three work on facial muscles, all three address dynamic wrinkles, and all three require no surgical recovery time. What is less commonly explained is how they actually differ from one another. Understanding the types of wrinkle relaxers available makes it easier to have a more informed conversation with a provider before booking a treatment.
This post explains how all three products work, what makes each one distinct, and what factors a provider typically considers when recommending one over another. The Botox and Wrinkle Relaxers service page provides an overview of the treatment options available and what the consultation process involves.
The existence of multiple wrinkle relaxer products on the market reflects both the growth of the aesthetic industry and the ongoing development of botulinum toxin formulations. Botox was the first product of its kind approved by the FDA for cosmetic use and has been in clinical use since 2002.
Over the following two decades, competing manufacturers developed alternative formulations using the same active mechanism but with different stabilizing ingredients, diffusion profiles, dosing units, and duration characteristics. Each product received separate FDA approval based on its own clinical trial data. The result is a market with several distinct options that share a common mechanism but differ in meaningful ways.
Understanding these differences helps patients and providers match the right product to the specific concern being treated. Knowing the types of wrinkle relaxers available is the first step in that process.
Before addressing the differences, it helps to establish what Botox, Dysport, and Daxxify all share. All three are botulinum toxin type A products. All three work by temporarily blocking the nerve signals that cause targeted facial muscles to contract. When the muscle cannot contract fully, the skin above it relaxes and the dynamic wrinkles that movement creates soften and become less visible.
All three are administered by injection, require no surgical recovery, and produce results that wear off naturally as nerve signals gradually return. All three are FDA-approved for cosmetic use in adults.
All three address the same general category of concern: dynamic expression lines, including frown lines between the brows, forehead creases, and crow’s feet.
According to the American Academy of Dermatology, botulinum toxin brand names include Botox Cosmetic, Dysport, Myobloc, and Xeomin, and when treating fine lines and wrinkles, the dermatologist injects the product into targeted muscles on the face or neck to temporarily relax them. Results typically last three to four months across the established product types.
All three products contain botulinum toxin type A as the active ingredient, but the surrounding formulation differs between them. These formulation differences produce distinct characteristics in each product. They affect how quickly results appear, how widely the product spreads from the injection site, and how long the results last.
Botox contains a form of botulinum toxin type A stabilized with human serum albumin and sodium chloride. It has the longest track record of clinical use and the most extensive safety data of the three.
Dysport contains a different form of botulinum toxin type A, also stabilized with albumin but with a different protein composition. Its unit dosing is not equivalent to Botox, meaning the number of units used differs between the two products.
Daxxify contains a novel form of botulinum toxin type A that replaces albumin with a proprietary stabilizing peptide. This peptide is what gives Daxxify its key advantage: a significantly longer duration of effect compared to the other two.
Botox is the product most people think of when they hear the word wrinkle relaxer. It has been FDA-approved for cosmetic use since 2002 and has the largest body of clinical research and real-world use of any botulinum toxin product on the market. This established track record is one reason it remains widely used despite the availability of newer options.
Key characteristics of Botox:
Botox is particularly well established for treating frown lines between the brows, forehead lines, and crow’s feet. Its reliability and predictability make it a common first choice for patients exploring the types of wrinkle relaxers for the first time.
Dysport received FDA approval for cosmetic use in 2009 and has been in clinical practice for many years with a strong safety profile. Its primary distinguishing characteristics are its faster onset of action and its tendency to spread more broadly from the injection site compared to Botox.
According to the Cleveland Clinic, Dysport may offer faster outcomes than Botox as a result of differences in the potency of trace proteins found in these medications, though Botox may last longer in some patients.
Key characteristics of Dysport:
The broader spread of Dysport requires the same level of provider skill as any other wrinkle relaxer. Precise placement ensures the product reaches the intended muscles without affecting unintended areas.
Daxxify received FDA approval in September 2022 and represents the most recent major advancement among the types of wrinkle relaxers available in the United States. Its defining characteristic is significantly longer duration compared to both Botox and Dysport.
The reason for this extended duration lies in its formulation. Daxxify replaces the human serum albumin used in Botox and Dysport with a proprietary positively charged peptide. This peptide helps the toxin bind more effectively to nerve surfaces, which is believed to extend how long the product remains active in the treated muscle.
According to the SAKURA 1 and SAKURA 2 Phase 3 clinical trials published in PubMed, 73.6% and 74.0% of subjects treated with Daxxify’s active ingredient achieved treatment success at week four. The median duration of response was significantly longer than that observed with Botox’s active ingredient in Phase 2 comparison studies. The median onset of a one-point improvement in frown line severity was three days.
Key characteristics of Daxxify:
Daxxify is currently FDA-approved for the treatment of moderate to severe frown lines between the brows in adults. Providers may also use it in other areas as experience with the product grows.
With several types of wrinkle relaxers now available, patients often wonder how a provider decides which one to recommend. The decision is based on a combination of clinical factors specific to the individual patient and the treatment areas being addressed.
Factors that influence product selection include:
The most reliable way to determine which product is right for a specific situation is through a consultation with a qualified provider who can assess facial anatomy, discuss treatment goals, and recommend the appropriate option.
Yes. These products are not mutually exclusive, and patients switch between them for a variety of reasons. The dosing units are different between products, so the provider will adjust the dose accordingly when switching. Communicating your previous product and the result you experienced helps the provider plan the transition.
All three are FDA-approved and have established safety profiles from clinical trials and real-world use. Botox has the most extensive long-term safety data due to its longer history. Dysport and Daxxify have both demonstrated strong safety profiles in their respective clinical programs. The safety of any wrinkle relaxer treatment depends significantly on the skill of the provider and the accuracy of the injection technique.
Daxxify has demonstrated a longer median duration than Botox in clinical studies. However, individual responses vary. Some patients find Daxxify lasts significantly longer, while others see results comparable to their previous product. Duration is also affected by the area treated, the dose used, and individual metabolism.
When administered correctly by a skilled provider, all three products should produce natural-looking results that reduce expression lines while preserving the ability to make facial expressions. Differences in outcome are more often related to provider technique and product dosing than to the product itself.
This is best determined at a consultation. Many providers recommend starting with Botox when a patient is new to the types of wrinkle relaxers, due to its long track record and well-characterized behavior. The right starting point depends on the specific treatment areas, the patient’s goals, and the provider’s clinical judgment.
Understanding the types of wrinkle relaxers available gives you a stronger foundation for the consultation conversation. Rather than relying entirely on the provider to explain the options from scratch, arriving with a basic understanding of how the products differ allows the discussion to focus on what is right for your specific situation.
Questions worth raising at a consultation for wrinkle relaxers:
A provider who can answer these questions clearly and specifically is one who understands the differences between the products they offer. For patients preparing for their first appointment, the post on what to know before getting Botox for the first time covers the full preparation picture from the patient’s perspective.
Those in the Lutz area who want to explore wrinkle relaxer options with a qualified provider can find more information at the Botox in Lutz, FL page.
If you have been comparing wrinkle relaxer options and want to understand which product best fits your concerns, schedule, and treatment goals, speaking with a qualified provider during a consultation is the most reliable way to get a personalized recommendation.
Personalized aesthetic and wellness care designed to help you look refreshed, feel confident, and support your well-being from the inside out.
Website Designed by IL Webdesign